- DKK51.19bn
- DKK58.42bn
- DKK24.63bn
'A tougher narrative into 2024' - MS starts Lundbeck with 'underweight'
Europe Research Roundup: BAE Systems, Entain, L'Oreal
Brief: Lundbeck Q3 EBITDA DKK 1,385 Million
Brief: H Lundbeck Narrows Full-Year Guidance For Revenue
Brief: Lundbeck, Otsuka Announce Topline Results From Two Phase III Trials
Brief: H Lundbeck Raises Its Full-Year Guidance For 2023
Brief: Lundbeck Raises FY Guidance
Brief: H Lundbeck Appoints Charl Van Zyl As New President And CEO
Brief: Lundbeck BOD member Jakob Riis Buys Shares In Co For About DKK 2 Mln
Europe Research Roundup: Ahold Delhaize, Diploma, Genmab A/S
Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drug (updated)
Brief: Lundbeck And Otsuka Announce U.S. FDA's Approval Of SNDA For Rexulti® (Brexpiprazole) For The Treatment Of Dementia Due To Alzheimer's Disease
Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drug
Otsuka And Lundbeck Announce U.S. FDA Approval Of Supplemental New Drug Application For Rexulti® (Brexpiprazole) For The Treatment Of Agitation Associated With Dementia Due To Alzheimer’s Disease
Brief: Lundbeck Sees FY Adj. EBITDA DKK 5.1-5.5 Billion
Brief: Lundbeck Announces Positive Phase II Proof Of Concept Results With Lu Ag09222 In Migraine Prevention
Europe Research Roundup: Accor, L'Oréal, Volvo
Brief: Lundbeck Q4 Reported EBIT Up At DKK 403 Mln
Brief: Lundbeck Sees FY 2023 Revenue At DKK 19.4 - 20.0 Bln